Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended‐Release Products

Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended‐Release Products

Publication: J Clin Pharmacol
Software: DDDPlus™

The University of Florida Center for Pharmacometrics and Systems Pharmacology and the Food and Drug Administration Office of Generic Drugs have collaborated on a research project to develop...

Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended‐Release Case Study

Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended‐Release Case Study

Publication: J Clin Pharmacol

The objective of this research was to evaluate the impact of changes in the formulation of metoprolol extended‐release (ER) tablets on dissolution, pharmacokinetic, and exercise‐induced heart rate (EIHR) using...

Oxysterols and apolipoproteins in multiple sclerosis: a 5-year follow-up study

Oxysterols and apolipoproteins in multiple sclerosis: a 5-year follow-up study

Publication: J Lipid Res

The purpose of this work was to investigate whether changes in oxysterol and apolipoprotein levels over 5 years are associated with...

Discovery of Membrane Permeability, Pharmacokinetics Properties and Mechanism of Action for Analogs of Ethylenediamine-N,N′-di-2-(3-Cyclohexyl)Propionic Acid and 1,3-Propandiamine-N,N′-di-2-(3-Cyclohexyl)Propionic Acid with Antiproliferative Activity Using In Vitro and In Silico Methods

Discovery of Membrane Permeability, Pharmacokinetics Properties and Mechanism of Action for Analogs of Ethylenediamine-N,N′-di-2-(3-Cyclohexyl)Propionic Acid and 1,3-Propandiamine-N,N′-di-2-(3-Cyclohexyl)Propionic Acid with Antiproliferative Activity Using In Vitro and In Silico Methods

Publication: IFMBE Proc
Software: ADMET Predictor®
Division: PBPK

In previously in vitro studies on different cell lines and in vivo on melanoma and 4T1 murine breast cancer and metastasis it was shown antiproliferative activity for ester derivatives of (S,S)-ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoic acid, and (S,S)-1,3-propanediamine-N,N′-di-2-(3-cyclohexyl)propanoic acid.

Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer

Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer

Publication: Journal of Cancer Research and Therapeutic Oncology

We sought to evaluate androgen receptor (AR) and PI3K pathway activity in ovarian cancer cell lines and tissue and determine if either pathway was correlated with growth...

In Silico and in Vitro Simulations to Predict Idiosyncratic DILI: What is on the Horizon?

In Silico and in Vitro Simulations to Predict Idiosyncratic DILI: What is on the Horizon?

Authors: Howell BA
Conference: DILI
Software: DILIsym®

Multiple species: human, rat, mouse, and dog, Population variability, The three primary acinar zones of liver represented, Essential cellular processes represented to multiple scales in interacting submodels...

Assessing and Managing DILI Risk in Trials: A Consultant’s Perspective

Assessing and Managing DILI Risk in Trials: A Consultant’s Perspective

Authors: Watkins PB
Conference: DILI
Software: DILIsym®

DILI typically has drug-specific “signatures”: Hepatocellular, cholestatic, mixed (R-value), Latency “window,” Rate of progression, rate of resolution, Extra-hepatic manifestations (e.g. hypersensitivity signs)

Assessing Effects of BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym®

Assessing Effects of BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym®

Conference: DILI
Software: DILIsym®

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of motor neurons that leads to progressive muscle weakness and difficulties in speaking, swallowing, and breathing.

In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation

In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation

Publication: Pharmaceutics
Software: GastroPlus®

A biowaiver is accepted by the Brazilian Health Surveillance Agency (ANVISA) for immediate-release solid oral products containing Biopharmaceutics Classification System (BCS) class I drugs showing rapid drug dissolution.

The Discriminatory Power of the BCS-based Biowaiver: A Retrospective with Focus on Essential Medicines

The Discriminatory Power of the BCS-based Biowaiver: A Retrospective with Focus on Essential Medicines

Publication: J Pharm Sci
Software: GastroPlus®

This article summarizes historic developments, recent expert opinions and (currently) unresolved challenges concerning the Biopharmaceutics Classification System (BCS) based biowaiver.

Analysis of pharmacological mechanisms and targets mining of Wuzi-Yanzong-Wan for treating non-obstructive oligoasthenospermia

Analysis of pharmacological mechanisms and targets mining of Wuzi-Yanzong-Wan for treating non-obstructive oligoasthenospermia

Publication: Biomed Pharmacother
Software: MedChem Studio™

As a classical traditional Chinese medicine, Wuzi-Yanzong-Wan (WZYZW) has been widely applied for several centuries to treat non-obstructive oligoasthenozoospermia (NOA), although its pharmacological mechanisms remain largely unknown.

Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling

Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling

Publication: Molecules

Tozadenant is one of the selective adenosine A2a receptor antagonists with a potential to be a new Parkinson’s disease (PD) therapeutic drug. In this study, a liquid chromatography-massspectrometry ...

Cu-mediated synthesis of differentially substituted diazepines as AChE inhibitors; validation through molecular docking and Lipinski’s filter to develop novel anti-neurodegenerative drugs

Cu-mediated synthesis of differentially substituted diazepines as AChE inhibitors; validation through molecular docking and Lipinski’s filter to develop novel anti-neurodegenerative drugs

Publication: Bioorg Med Chem

A highly efficient Cu-mediated route for the synthesis of fused [1,2,3]triazolo[1,4]diazepines has been developed by azidation-cyclization of 2-bromo-N-propargylamines in a one-pot fashion.

GastroPlus® User Group Webinar: Applications/Experiences of PBPK Modeling to Support Regulatory Interactions

GastroPlus® User Group Webinar: Applications/Experiences of PBPK Modeling to Support Regulatory Interactions

Software: GastroPlus®
Division: PBPK

Recent experiences with PBPK model-based regulatory submissions used to obtain product development and DDI waivers will be discussed.